Tag: 3 Drug Combo

cancer-1-770x433
3-drug combo improves survival period for bowel cancer patients

London: A targeted three-drug combination therapy resulted in median overall survival of nine months for patients with advanced bowel cancer compared to 5.4 months for current standard-of-care treatment, showed the results of a phase-3 clinical trial. The data suggested that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal […]

  • Wednesday, 28 April 2021
scrollToTop